Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.670955 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.670955 34093569!8172170!34093569     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 670955 Nephropedia Template TP {{tp|p=34093569|t=2021. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?|pdf=|usr=}}{{34093569}} gab.com Text Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19 JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34093569 #FOAvip The pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has led to an extraordinary threat to the global healthcare system. This infection disease, named COVID-19, is characterized by a wide clinical spectrum, ranging from asymptomatic or mild upper respiratory tract illness to severe viral pneumonia with fulminant cytokine storm, which leads to respiratory failure. To improve patient outcomes, both the inhibition of viral replication and of the unwarranted excessive inflammatory response are crucial. Since no specific antiviral drug has been proven effective for the treatment of patients and the only upcoming promising agents are monoclonal antibodies, inexpensive, safe, and widely available treatments are urgently needed. A potential anti-inflammatory molecule to be evaluated, which possesses antiviral activities in several experimental models, is the polyphenol resveratrol. This compound has been shown to inhibit SARS-CoV-2 replication in human primary bronchial epithelial cell cultures and to downregulate several pathogenetic mechanisms involved in COVID-19 severity. The use of resveratrol in clinical practice is limited by the low bioavailability following oral administration, due to the pharmacokinetic and metabolic characteristics of the molecule. Therefore, topical administration through inhaled formulations could allow us to achieve sufficiently high concentrations of the compound in the airways, the entry route of SARS-CoV-2. Twit Text FOAVip Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19 ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34093569 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34093569 #FOAvip English Wikipedia <ref>{{Cite pmid|34093569}}</ref> Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19? #MMPMID34093569 Rossi GA; Sacco O; Capizzi A; Mastromarino P Front Immunol 2021[]; 12 (ä): 670955 PMID34093569show ga The pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has led to an extraordinary threat to the global healthcare system. This infection disease, named COVID-19, is characterized by a wide clinical spectrum, ranging from asymptomatic or mild upper respiratory tract illness to severe viral pneumonia with fulminant cytokine storm, which leads to respiratory failure. To improve patient outcomes, both the inhibition of viral replication and of the unwarranted excessive inflammatory response are crucial. Since no specific antiviral drug has been proven effective for the treatment of patients and the only upcoming promising agents are monoclonal antibodies, inexpensive, safe, and widely available treatments are urgently needed. A potential anti-inflammatory molecule to be evaluated, which possesses antiviral activities in several experimental models, is the polyphenol resveratrol. This compound has been shown to inhibit SARS-CoV-2 replication in human primary bronchial epithelial cell cultures and to downregulate several pathogenetic mechanisms involved in COVID-19 severity. The use of resveratrol in clinical practice is limited by the low bioavailability following oral administration, due to the pharmacokinetic and metabolic characteristics of the molecule. Therefore, topical administration through inhaled formulations could allow us to achieve sufficiently high concentrations of the compound in the airways, the entry route of SARS-CoV-2. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Administration, Inhalation[MESH] |Animals[MESH] |Anti-Inflammatory Agents/pharmacokinetics/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Biological Availability[MESH] |COVID-19/immunology[MESH] |Cytokine Release Syndrome/*drug therapy/immunology[MESH] |Humans[MESH]Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct T(epmc).pdf DeepDyve Pubget Overpricing